SAB Biotherapeutics
SABS
34 hedge funds and large institutions have $2.41M invested in SAB Biotherapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 7 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
0.55% less ownership
Funds ownership: 7.85% → 7.31% (-0.55%)
11% less funds holding
Funds holding: 38 → 34 (-4)
27% less capital inflows, than outflows
Capital inflows: $448K | Capital outflows: $617K
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pathstone Family Office
Englewood,
New Jersey
|
+$372K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$41K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$20.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.4K |
| 5 |
Renaissance Technologies
New York
|
+$2.72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bridgeway Capital Management
Houston,
Texas
|
-$69.7K |
| 2 |
Silver Oak Securities
Jackson,
Tennessee
|
-$43K |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$30K |
| 4 |
Virtu Financial
New York
|
-$21K |
| 5 |
Two Sigma Investments
New York
|
-$20.8K |
SABS Hedge Fund Activity: Q3 2023 in Review
34 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q3 2023, worth a combined $2.41M — down 27% from $3.28M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SABS and 3 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 7 added.
The largest buyer was Pathstone Family Office, opening a new position worth an estimated $372K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $69.7K sold.
- 34 institutional investors held SAB Biotherapeutics (SABS) as of Q3 2023, down from 38 in Q2 2023.
- Funds reported $2.41M of SAB Biotherapeutics stock for Q3 2023, down 27% quarter-over-quarter.
- 3 funds opened new SAB Biotherapeutics positions in Q3 2023 and 7 closed out, a net change of -4 holders.
- The largest SAB Biotherapeutics buyer in Q3 2023 was Pathstone Family Office, an estimated $372K added.
- The largest SAB Biotherapeutics seller in Q3 2023 was Bridgeway Capital Management, an estimated $69.7K sold.
Based on aggregated 13F filings for Q3 2023.